Dr. Byrne received her PhD in cell biology from the University of York, UK in 1999. Following this, Dr. Byrne was awarded the John Kerner fellowship in Gynaecologic Oncology from the University of California, San Francisco. During this period she was engaged in the elucidation of novel angiogenesis targets important in the development of ovarian cancer, as well as screening the in vivo activity of novel targetd therapeutics.

Subsequently, Dr. Byrne was recruited by Pharmacyclics Inc, a medium sized pharmaceutical company in California’s ‘silicon valley’ to investigate the mechanism of action of a new class of radiation/chemotherapy sensitizersunder clinical development. In 2003, she moved to Angion Biomedica Corp., whose main focus was developing therapeutics to manipulate angiogenesis signaling pathways. Dr. Byrne returned to Ireland in 2005 to the position of Principal Investigator at University College Dublin’s Conway Institute and in collaboration with Prof Gallagher, was instrumental in establishing Ireland’s first comprehensive Tumour Xenograft Facility and translational in vivo imaging activities. “. In 2008, Dr. Byrne was appointed as Lecturer & Principal Investigator at RCSI and in 2013 was promoted to Senior Lecturer in the Dept of Physiology & Medical Physics. Her research focuses primarily on the systems-based application of molecular imaging strategies in the evolution of cancer biomarkers & targeted therapies. Her work is primarily supported by EU-FP7, Science Foundation Ireland (SFI), Health Research Board (HRB), and the Clinical Cancer Research Trust awards.